HeartSciences Inc.

HeartSciences Inc. is a U.S.-based medical technology company developing AI-enabled electrocardiography tools that aim to make a standard ECG more clinically useful. Its core products are the cloud-based MyoVista Insights platform and the MyoVista wavECG device, both designed to detect a broader range of cardiac conditions, but neither has yet received FDA marketing clearance.

−194 143,9 %

59,1 %

−211 666,5 %

−0,7 %

0.53

0.40

— HeartSciences Inc.
%
Cloud ECG management platform20% MyoVista Insights provides ECG upload, centralized storage, review, and AI algorithm delivery in clinical workflows.
AI-ECG algorithms25% Proprietary and licensed algorithms intended to detect cardiac dysfunction and other heart disease conditions.
MyoVista wavECG device30% A proprietary resting 12-lead ECG device designed to combine conventional ECG output with AI-derived diagnostic information.
Consumables and test-related accessories15% Proprietary electrodes and related components used with the wavECG device on a per-test basis.
Platform licensing and third-party hosting10% Hosting and commercialization of third-party AI-ECG algorithms on the MyoVista Insights platform.

HeartSciences sells into healthcare providers and payors that want better cardiac screening, workflow efficiency, and...

  • Hospitals and health systemsprimary

    Buy the cloud platform and, later, the wavECG device to improve ECG workflow, storage, and diagnostic reach.

  • Cardiologists and referring physiciansprimary

    Use the platform and device outputs to support diagnosis and referral decisions for cardiac disease.

  • Primary care and point-of-care providerssecondary

    Adopt the device or cloud workflow for front-line screening where faster triage can improve referral quality.

  • Managed care and Medicare Advantage ecosystemssecondary

    Potential buyers or influencers because better detection of heart disease can support risk adjustment and care management.

  • Early adopter clinical sitesemerging

    Pilot the MyoVista Insights platform to validate workflow fit and prepare for future algorithm deployment.

HeartSciences is headquartered in the United States, but its commercialization strategy is global and explicitly...

  • •Headquartered in the United States
  • •Commercial model is intended to be worldwide
  • •Historical revenue came mainly from non-U.S. distributor relationships
  • •U.S. commercialization depends on FDA clearance and reimbursement
  • •International reimbursement varies by country and can slow adoption

The company is building a device-agnostic AI-ECG platform first, then layering in its own MyoVista wavECG hardware and...

01
FDA clearance and regulatory pathway executionshort-term

Commercial sales in the U.S. depend on clearance for the device and future algorithms.

02
Clinical workflow adoption and early customer validationshort-term

The platform must fit into existing workflows to gain physician and facility acceptance.

03
Platform expansion through third-party algorithmsmedium-term

Hosting external algorithms can increase clinical value and reduce internal development cost.

04
Recurring revenue model developmentmedium-term

Subscriptions, algorithm usage, and consumables can create more durable revenue than one-time device sales.

HeartSciences is still pre-commercial in its core products, so regulatory clearance, reimbursement, and physician...

critical

Regulatory clearance delay or failure

The company cannot market the wavECG in the U.S. without FDA clearance, and future algorithms also require regulatory pathways.

Scope
MyoVista wavECG and future AI-ECG algorithms
Materiality
high
critical

Insufficient funding and going-concern pressure

The company has limited cash, recurring losses, and expects to rely on equity financing to continue operations.

Scope
R&D, commercialization, working capital
Materiality
high
high

Reimbursement and coverage uncertainty

Hospitals and payors may not adopt products without coverage, especially for AI-ECG use cases.

Scope
U.S. and international commercialization
Materiality
high
high

Physician and customer acceptance

Adoption depends on clinicians believing the products are useful, reliable, and easy to integrate.

Scope
Cardiologists, referring physicians, early adopters
Materiality
medium
medium

Supplier and manufacturing dependence

The device relies on third-party components and assembly, creating quality, cost, and delivery risk.

Scope
MyoVista wavECG hardware and consumables
Materiality
medium
medium

Nasdaq listing compliance and dilution

Ongoing losses and equity financing can pressure listing status and dilute shareholders.

Scope
Capital markets access
Materiality
medium
Revenue recognition for device, software, and algorithm offerings
Could materially affect reported revenue timing and gross margin
Stock-based compensation
Affects operating expenses and net loss
Going-concern and liquidity disclosures
Important for solvency assessment and capital-raising expectations
Fair value measurement of financing instruments
Can create volatility in other income/expense and equity balances

HeartBeam, Inc.

BEAT · Surgical & Medical Instruments & Apparatus

Heartflow, Inc.

HTFL · Surgical & Medical Instruments & Apparatus

iRhythm Holdings, Inc.

IRTC · Surgical & Medical Instruments & Apparatus

Cardio Diagnostics Holdings, Inc.

CDIO · In Vitro & In Vivo Diagnostic Substances

PULSE BIOSCIENCES, INC.

PLSE · Surgical & Medical Instruments & Apparatus

Odyssey Health, Inc.

ODYY · Surgical & Medical Instruments & Apparatus

: 28/04/2026